Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Amylin Battle Heats Up as Eastbourne Capital Touts Rival Directors' Slate to Icahn's
- Eastbourne Capital has proposed a five-member team of its own for Amylin's board. Carl Icahn proposed his own slate last week. Both sets of investors are unhappy with the company that has a joint venture with Eli Lilly on diabetes drug Byetta. Eastbourne said of its move:...
- Blog posts 2009-02-02
- Amylin Founder Resigns, Suggests Chairman Follow; Icahn and Eastbourne Likely Delighted
- The Amylin board of directors is crumbling in its resistance to insurgent investors Carl Icahn and Eastbourne Capital. Amylin founder Howard Greene resigned as director and wrote a letter suggesting that chairman Joseph Cook should also step down. Greene said he won’t vote for Cook because: A majority of...
- Blog posts 2009-04-10
- Amylin v. Eastbourne Slideshow Battle; It's All About the Stock Price
- Amylin and Eastbourne Capital, locked in a fight for control of Amylin's board of directors, have escalated their war in the only way that beancounters know how: duelling presentations. You can see Amylin's here and a summary of Eastbourne's here. Eastbourne has kept it...
- Blog posts 2009-05-06
Additional Resources
- In War for Amylin, Icahn and Eastbourne Win a Battle; "Poison Pill" Remains
- Carl Icahn and Eastbourne Capital seem to have won a small battle in their war for Amylin. The company's board has decided not to commit financial suicide in the face of their insurgent board election bid. by Jim Edwards
- Blog posts 2009-04-16
- Amylin Sales Force Is Least-Effective Among Its Peers, Claims Eastbourne
- An analysis of drug sales force effectiveness by Eastbourne Capital shows ImClone coming top and Amylin coming bottom among companies of similar size. Gilead comes in second best. by Jim Edwards
- Blog posts 2009-05-12
- Amylin's Eastham Says Eastbourne's Behrens Is Not Telling the Truth About $20 Share Bid
- Amylin director Karin Eastham has, in essence, called Eastbourne Capital board candidate M. Kathleen Behrens a liar or at least an amnesiac. by Jim Edwards
- Blog posts 2009-05-14
- Amylin: Icahn, Eastbourne Celebrate Disposal of Chairman
- Todd Walker submits: Last week it was announced that activist investors Carl Icahn and Eastbourne Capital Management had successfully elected Dr. Alexander J. Denner and Dr. Kathleen Behrens, respectively, to the board of directors of Amylin Pharmaceuticals AMLN. On Tuesday, the activists received even more good news when they learned...
- External links 2009-06-04
- The War for Amylin: Lilly Not Interested; Icahn Calls the Company a "Dictatorship"
- Eli Lilly CEO John Lechleiter complicated the battle for Amylin today by telling Reuters he was not interested in buying the company. It was widely suspected that investor Carl Icahn, who is in a three-way war for control of Amylin's board of directors, wants to dress up...
- Blog posts 2009-04-28
- Inside Amylin's Anti-Icahn Suicide Pact
- Amylin has adopted a financial suicide pact which, in the company's own words, may bankrupt the company if dissident investors Carl Icahn and Eastbourne Capital get a majority of directors elected at the May 27 shareholder meeting. The pact is described in a lawsuit brought by a...
- Blog posts 2009-04-01
- Amylin Q1: "Icahn Doesn't Know Who Our CEO Is"
- Amylin filed a sarcastic letter describing phone conversations it had with angry investor Carl Ichan over the past few days. "Sarcastic," because the final point in the letter which you can read here is this: Finally, on our call you asked, "Who is Dan Bradbury?" Dan Bradbury is Amylin’s...
- Blog posts 2009-04-20
- Amylin Insists Byetta Doesn't Cause Cancer; Wall Street Doesn't Seem So Sure
- Amylin CEO Daniel Bradbury may be wishing that Novo Nordisk's failed competitor to its diabetes drug Byetta had actually been approved by the FDA. Had Novo's liraglutide passed muster, no one would have gotten the jitters over whether Byetta gives you cancer or not. At Amylin's conference...
- Blog posts 2009-04-21
- What Amylin's Established Drugs Are Worth Alone
- Vincent Fernando submits: Admittedly, my blog has become a bit of a war room in regard to the special situation surrounding Amylin AMLN shares these days. I personally find it to be an extremely interesting special situation and now have exposure to the shares. A lot of analysis...
- External links 2009-05-13
- Amylin CEO Got 11% Pay Rise Despite Losses; Company Paid $355K for Lawyer to Move House
- Combined executive pay at Amylin rose 10.2 percent last year even though the company lost 50 percent more money than it did the year before, according to a filing with the SEC. Amylin has not made a profit in the last five years, despite its revenues going from zero to...
- Blog posts 2009-04-22
- Amylin Accused of Spreading "Baseless Accusations," "Innuendo" and Misusing CNBC in Director Fight
- The battle for control of Amylin's board of directors has entered a gossipy phase. One of Eastbourne Capital's director candidates has written to Amylin claiming the board has been spreading "baseless accusations[s]" and "innuendo" about her, and CNBC's Mike Huckman has objected to the way Amylin has quoted him in...
- Blog posts 2009-05-13
- In War for Amylin, Insurgents Gain Ground in Final Days Before Vote
- It's the home stretch of the Amylin proxy fight, in which Carl Icahn and Eastbourne Capital are trying to persuade shareholders to let them take control of Amylin. So who's winning? Until a few days ago, it looked like Amylin. But the insurgents appear to have won a few arguments...
- Blog posts 2009-05-21
- Key Amylin Catalyst Expected Wednesday
- Vincent Fernando submits: A major battle for change at Amylin Pharmaceuticals AMLN could be decided this Wednesday when the company has its annual shareholder meeting and shareholders vote for a potentially new slate of board members put forward by activist shareholders Carl Icahn and Eastbourne Capital. Nevertheless, despite heated...
- External links 2009-05-24
- Dissidents Elect 2 to Amylin Board; So Who Won the War?
- The results of the shareholder vote for control of Amylin's board of directors are in: dissident investors Eastbourne Capital and Carl Icahn now have two directors on the board one each. They had proposed a slate of five for the 12-member board. So who won? by Jim Edwards
- Blog posts 2009-05-28
- Amylin CEO Bradbury Loses Chairman, Lead Director: Will He Be Next?
- Can Amylin CEO Dan Bradbury survive now that he has lost his board chairman and lead director to nominees selected by insurgent investors Carl Icahn and Eastbourne Capital? by Jim Edwards
- Blog posts 2009-06-03
- CVC to bid for water supplier.
- CVC Capital Partners, the private equity firm at the heart of the Debenhams bidding battle, is set to make a cash offer of about [pounds sterling]350m ([euro]498m) for South East Water.The private equity firm will make an indicative bid on Friday for South East, which supplies ...
- Research articles 2003-09-17
- << Previous
- page 1 of 1
- Next >>
